NeOnc Technologies Holdings, Inc. Common Stock (NTHI) - Total Liabilities
Based on the latest financial reports, NeOnc Technologies Holdings, Inc. Common Stock (NTHI) has total liabilities worth $16.56 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore NTHI net asset momentum to track the company's year-over-year net asset growth rate.
NeOnc Technologies Holdings, Inc. Common Stock - Total Liabilities Trend (2021–2025)
This chart illustrates how NeOnc Technologies Holdings, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See NeOnc Technologies Holdings, Inc. Common free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
NeOnc Technologies Holdings, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of NeOnc Technologies Holdings, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Krystal Integrated Services Ltd
NSE:KRYSTAL
|
India | Rs3.42 Billion |
|
Consti Yhtiot Oy
HE:CONSTI
|
Finland | €71.71 Million |
|
Kencana Agri Limited
F:KEBA
|
Germany | €206.68 Million |
|
Adocia
PA:ADOC
|
France | €26.96 Million |
|
Bionet
TWO:1784
|
Taiwan | NT$822.58 Million |
|
Federal Mogul Izmit Piston ve Pim Uretim Tesisleri AS
IS:FMIZP
|
Turkey | TL86.23 Million |
|
Raute Oyj
HE:RAUTE
|
Finland | €47.19 Million |
|
La Kaffa International Co Ltd
TWO:2732
|
Taiwan | NT$3.92 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down NeOnc Technologies Holdings, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NeOnc Technologies Holdings, Inc. Common market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.97 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NeOnc Technologies Holdings, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NeOnc Technologies Holdings, Inc. Common Stock (2021–2025)
The table below shows the annual total liabilities of NeOnc Technologies Holdings, Inc. Common Stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $20.33 Million | +127.87% |
| 2024-12-31 | $8.92 Million | -41.51% |
| 2023-12-31 | $15.25 Million | +562.02% |
| 2022-12-31 | $2.30 Million | -13.01% |
| 2021-12-31 | $2.65 Million | -- |
About NeOnc Technologies Holdings, Inc. Common Stock
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical… Read more